Revised forecast
Fiscal year ending March 2027 · Full yearPrevious forecast published Disclosed on 14 May 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document.
Increased demand for pharmaceutical intermediates and active pharmaceutical ingredients, the launch of mass production for newly developed products, and increased overseas sales contributed to performance. In addition, as reasonable calculation of profit became possible based on business performance through the interim period and the current business environment, new profit forecasts were disclosed.
| Item | Details |
|---|---|
| Net Sales | ¥11,600 million → ¥12,500 million（+7.8%） |
| Operating profit | Not disclosed → ¥1,100 million |
| Ordinary income | Not disclosed → ¥1,250 million |
| Profit attributable to owners of the parent | Not disclosed → ¥950 million |
| Net income per share | Not disclosed → ¥115.23 / sen |
| Fiscal Period Covered | Fiscal year ending March 2027 |
| Period Covered | Full year |
| Publication date of previous forecast | Disclosed on 14 May 2026 |
| Previous-period results | Net Sales ¥10,993 million / Operating profit ¥739 million / Ordinary income ¥825 million / Profit attributable to owners of the parent ¥781 million / Net income per share ¥95.97 / sen |
| Reason for the revision | Increased demand for pharmaceutical intermediates and active pharmaceutical ingredients, the launch of mass production for newly developed products, and increased overseas sales contributed to performance. In addition, as reasonable calculation of profit became possible based on business performance through the interim period and the current business environment, new profit forecasts were disclosed. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In addition to increased demand for pharmaceutical intermediates and active pharmaceutical ingredients, the launch of mass production for newly developed products, including semiconductor-related products, and increased overseas sales contributed to net sales. In addition, based on business performance through the interim period and the current business environment, it became possible to reasonably calculate profit forecasts.